Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Bibliographic Details
Main Authors:	Yu-Yang Liu, Yi-Yang Qu, Shang Wang, Ci-Jun Luo, Hong-Ling Qiu, Hui-Ting Li, Ping Yuan, Lan Wang, Jin-Ling Li, Rong Jiang, Rui Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-02-01
Series:	Frontiers in Pharmacology
Subjects:	pulmonary arterial hypertension riociguat systematic review meta, analysis phosphodiesterase-5 inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1155631/full

Similar Items

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
by: Yu-Yang Liu, et al.
Published: (2023-01-01)

Modern view on the place of riociguat in the treatment of pulmonary hypertension
by: Z S Valieva, et al.
Published: (2018-04-01)

Modern view on the place of riociguat in the treatment of pulmonary hypertension
by: Z.S. Valieva, et al.
Published: (2018-04-01)

Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat
by: Tamila V. Martynyuk, et al.
Published: (2021-09-01)

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
by: Humberto García Aguilar, et al.
Published: (2022-07-01)

Treatment of patients with chronic thromboembolic pulmonary hypertension: focus on riociguat
by: Smith ZR, et al.
Published: (2016-06-01)

Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
by: N. H. Kim
Published: (2010-03-01)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
by: Vallerie V. McLaughlin, et al.
Published: (2017-12-01)

Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: N. A. Tsareva, et al.
Published: (2016-12-01)

Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective
by: Mihalek AD, et al.
Published: (2022-10-01)

Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results
by: E. V. Filippov
Published: (2020-12-01)

Identification and toxicity profiling of degradation impurities of riociguat using tandem mass spectrometry and in-silico studies
by: Rahul S Chodankar, et al.
Published: (2022-11-01)

Riociguatas the first innovative guanylatecyclase stimulators class drugs for pulmonary arterial hypertension patients treatment
by: I E Chazova, et al.
Published: (2013-12-01)

Repurposing Riociguat to Target a Novel Paracrine Nitric Oxide-TRPC6 Pathway to Prevent Podocyte Injury
by: Daan ‘t Hart, et al.
Published: (2021-11-01)

The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
by: S. E. Gratsianskaya, et al.
Published: (2020-10-01)

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
by: Asger Andersen, et al.
Published: (2017-01-01)

Riociguat inhibits ultra‐large VWF string formation on pulmonary artery endothelial cells from chronic thromboembolic pulmonary hypertension patients
by: Takayuki Jujo Sanada, et al.
Published: (2022-10-01)

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide
by: L. T. Domingo, et al.
Published: (2022-12-01)

Repurposing Riociguat for Treatment of Refractory Angina Resulting From Coronary Spasm
by: Valeria Martínez Pereyra, MS, et al.
Published: (2021-03-01)

Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension
by: Erin M. Schikowski, et al.
Published: (2022-11-01)

Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy
by: H. A. Ghofrani, et al.
Published: (2009-03-01)

A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
by: Jin-Qiu Yuan, et al.
Published: (2016-01-01)

Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients
by: N. V. Marukyan, et al.
Published: (2021-05-01)

Modulating NO–GC Pathway in Pulmonary Arterial Hypertension
by: Anna D’Agostino, et al.
Published: (2023-12-01)

Inhibition of PDE‐4 isoenzyme attenuates frequency and overall contractility of agonist‐evoked ureteral phasic contractions
by: Iris Lim, et al.
Published: (2024-02-01)

Inhibition of PDE5 restores depressed baroreflex sensitivity in renovascular hypertensive rats
by: Clenia O Cavalcanti, et al.
Published: (2016-01-01)

Clinical Phenotype of <i>PDE6B</i>-Associated Retinitis Pigmentosa
by: Laura Kuehlewein, et al.
Published: (2021-02-01)

PDE4-Mediated cAMP Signalling
by: Bracy A. Fertig, et al.
Published: (2018-01-01)

A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?
by: N A Tsareva, et al.
Published: (2017-09-01)

Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region
by: Chloe Gulliver, et al.
Published: (2023-10-01)

Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data
by: M. A. Simakova, et al.
Published: (2020-05-01)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension
by: Eckhard Mayer, et al.
Published: (2014-01-01)

Effect of Phosphodiesterase-5 Inhibitors on the Treatment of Male Infertility: A Systematic Review and Meta-Analysis
by: Liang Dong, et al.
Published: (2021-10-01)

Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta‐analysis
by: Shang Wang, et al.
Published: (2024-02-01)

Imaging of PDE2- and PDE3-Mediated cGMP-to-cAMP Cross-Talk in Cardiomyocytes
by: Nikoleta Pavlaki, et al.
Published: (2018-01-01)

Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review
by: Diego Fernández-Lázaro, et al.
Published: (2023-01-01)

The evolution and structure of snake venom phosphodiesterase (svPDE) highlight its importance in venom actions
by: Cheng-Tsung Pan, et al.
Published: (2023-04-01)

Advances in Balloon Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
by: GAO Luyang, et al.
Published: (2023-09-01)

Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases
by: Vincent Lagente, et al.
Published: (2005-03-01)

Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs
by: D Yu Platonov, et al.
Published: (2017-12-01)